- Home
- GITS vs ACXP Comparison
GITS vs ACXP Comparison
Compare GITS & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- ACXP
- Stock Information
- Founded
- GITS 2018
- ACXP 2017
- Country
- GITS South Korea
- ACXP United States
- Employees
- GITS N/A
- ACXP N/A
- Industry
- GITS
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- ACXP Health Care
- Exchange
- GITS Nasdaq
- ACXP Nasdaq
- Market Cap
- GITS 7.2M
- ACXP 6.8M
- IPO Year
- GITS N/A
- ACXP 2021
- Fundamental
- Price
- GITS $1.80
- ACXP $6.80
- Analyst Decision
- GITS
- ACXP Strong Buy
- Analyst Count
- GITS 0
- ACXP 3
- Target Price
- GITS N/A
- ACXP $143.67
- AVG Volume (30 Days)
- GITS 153.8K
- ACXP 1.6M
- Earning Date
- GITS 11-19-2025
- ACXP 11-12-2025
- Dividend Yield
- GITS N/A
- ACXP N/A
- EPS Growth
- GITS N/A
- ACXP N/A
- EPS
- GITS N/A
- ACXP N/A
- Revenue
- GITS $29.00
- ACXP N/A
- Revenue This Year
- GITS N/A
- ACXP N/A
- Revenue Next Year
- GITS N/A
- ACXP N/A
- P/E Ratio
- GITS N/A
- ACXP N/A
- Revenue Growth
- GITS N/A
- ACXP N/A
- 52 Week Low
- GITS $0.87
- ACXP $3.80
- 52 Week High
- GITS $9.78
- ACXP $41.00
- Technical
- Relative Strength Index (RSI)
- GITS 33.44
- ACXP 63.75
- Support Level
- GITS $2.00
- ACXP $6.75
- Resistance Level
- GITS $2.33
- ACXP $7.98
- Average True Range (ATR)
- GITS 0.16
- ACXP 0.70
- MACD
- GITS -0.03
- ACXP 0.16
- Stochastic Oscillator
- GITS 30.21
- ACXP 63.93
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.